Preparation, characterization, and in vivo evaluation of a polymorphic form of valnemulin hydrogen tartrate

We prepared a polymorphic form of valnemulin hydrogen tartrate (Form I) to overcome the instability and irritating odor of valnemulin hydrochloride that affect its use in the production and application of veterinary drugs. The physicochemical properties of Form I were characterized by scanning electron microscopy, X-ray powder diffraction, infrared spectroscopy, differential scanning calorimetry, and thermogravimetric analysis. The results showed the crystal structure and thermal properties of Form I were very different from those of a commercially available form of valnemulin hydrogen tartrate (Form II). Form I and Form II were more stable than valnemulin hydrochloride after storage under irradiation and high humidity conditions, respectively. The solubility of Form I was 2.6 times that of Form II, and Form I was selected for use in pharmaceutical kinetics experiments in vivo. Compared to valnemulin hydrochloride, after oral administration at a dose of 10 mg/kg in pigs, Form I had similar pharmaceutical kinetic behavior but a slightly higher area under the concentration–time curve from time zero to the last measurable concentration. Consequently, Form I should be suitable for the development of simple formulations and be effective in the clinical application of veterinary drugs.

[1]  F. Sun,et al.  Pharmacokinetics of valnemulin after intravenous, intramuscular, and oral administration in layer chickens. , 2017, Journal of veterinary pharmacology and therapeutics.

[2]  R. Bodmeier,et al.  Evaluation of a biphasic in vitro dissolution test for estimating the bioavailability of carbamazepine polymorphic forms , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  J. Ao,et al.  A new polymorphic form of metoprolol succinate , 2017, Pharmaceutical development and technology.

[4]  PALATABILITY ENHANCERS AND METHODS FOR ENHANCING PALATABILITY CROSS REFERENCE TO RELATED APPLICATIONS , 2017 .

[5]  Abhishek Singh,et al.  Drug loaded and ethylcellulose coated mesoporous silica for controlled drug release prepared using a pilot scale fluid bed system. , 2016, International journal of pharmaceutics.

[6]  Xinle Zhu,et al.  Preparation of valnemulin hydrogen fumarate and its enhanced stability compared with valnemulin hydrochloride , 2016, Pharmaceutical development and technology.

[7]  B. Fang,et al.  Synthesis and Antimicrobial Activity of the Hybrid Molecules between Sulfonamides and Active Antimicrobial Pleuromutilin Derivative , 2015, Chemical biology & drug design.

[8]  Lucélia Magalhães da Silva,et al.  Quality evaluation of the Finasteride polymorphic forms I and II in capsules. , 2015, Journal of Pharmaceutical and Biomedical Analysis.

[9]  S. Ottani,et al.  Characterization of polymorphic ampicillin forms. , 2014, Journal of pharmaceutical and biomedical analysis.

[10]  H. Hao,et al.  Determination and correlation of solubility and solution thermodynamics of valnemulin hydrogen tartrate in different pure solvents , 2014 .

[11]  K. Moribe,et al.  Four new polymorphic forms of suplatast tosilate. , 2014, International journal of pharmaceutics.

[12]  Xiaojie Chen,et al.  SYNTHESIS AND IN VITRO ANTIBACTERIAL ACTIVITY OF FOUR NOVEL PLEUROMUTILIN DERIVATIVES , 2013 .

[13]  Y. Liu,et al.  Pharmacokinetics and bioavailability of valnemulin in Muscovy ducks (Cairina moschata) , 2012, British poultry science.

[14]  Yahong Liu,et al.  Pharmacokinetics and Lung Tissue Concentration of Valnemulin in Swine , 2011 .

[15]  Y. Liu,et al.  A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs. , 2011, Journal of veterinary pharmacology and therapeutics.

[16]  B. Fang,et al.  Pharmacokinetics and bioavailability of valnemulin in broiler chickens. , 2011, Journal of veterinary pharmacology and therapeutics.

[17]  Lei Dai,et al.  Mutations in 23S rRNA gene associated with decreased susceptibility to tiamulin and valnemulin in Mycoplasma gallisepticum. , 2010, FEMS microbiology letters.

[18]  L. H. Hansen,et al.  Single 23S rRNA mutations at the ribosomal peptidyl transferase centre confer resistance to valnemulin and other antibiotics in Mycobacterium smegmatis by perturbation of the drug binding pocket , 2009, Molecular microbiology.

[19]  S. Palacios,et al.  Solid-state characterization of two polymorphic forms of R-albuterol sulfate. , 2007, Journal of pharmaceutical and biomedical analysis.

[20]  L. Stipkovits,et al.  The efficacy of valnemulin (Econor) in the control of disease caused by experimental infection of calves with Mycoplasma bovis. , 2005, Research in veterinary science.

[21]  주잔네 크리스티네 빌란트베르크하우젠,et al.  Micropherules containing a pleuromutilin derivative , 2002 .

[22]  L. Stipkovits,et al.  Use of valnemulin in the control of Mycoplasma bovis infection under field conditions , 2001, Veterinary Record.

[23]  D. Burch,et al.  In vitro and in vivo comparisons of valnemulin, tiamulin, tylosin, enrofloxacin, and lincomycin/spectinomycin against Mycoplasma gallisepticum. , 1998, Avian diseases.

[24]  J. Guillory,et al.  Polymorphism in sulfonamides. , 1972, Journal of pharmaceutical sciences.

[25]  R. Mesley,et al.  Infrared identification of barbiturates with particular reference to the occurrence of polymorphism , 1968, The Journal of pharmacy and pharmacology.